StreetInsider.com News Articles

VivoSim Labs presents drug toxicity data at EUROTOX 2026

Wed, 16 Sep 2026 08:05:43 -0400

VivoSim Labs, Inc. (NASDAQ: VIVS) presented new data from its NAMkind™ 3D human tissue platforms at the 58th Congress of the European Societies of Toxicology (EUROTOX 2026) in Vienna, Austria, on Sept. 16, 2026, showing the platforms' ability to predict liver and gastrointestinal drug toxicity across small molecules and Antibody-Drug Conjugates (ADCs).

The company's NAMkind™ Liver platform supports liver spheroid viability for up to 28 days, while its intestinal models maintain barrier integrity for up to three weeks. According to the press release, this extended culture duration allows researchers to evaluate repeat-dose effects that shorter laboratory assays may not capture.

In studies

VivoSim Labs presents drug toxicity data at EUROTOX 2026

Wed, 16 Sep 2026 08:05:43 -0400

In studies

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

Wed, 16 Sep 2026 08:05:00 -0400

New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities

SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ: VIVS) (“VivoSim” or the “Company”) unveils new clinical benchmark data at the 58th Congress of the European Societies of Toxicology (EUROTOX 2026) in Vienna, Austria, demonstrating the ability of its NAMkind™ 3D human liver and intestinal platforms to predict drug toxicity across small molecules and increasingly complex therapies, including Antibody-Drug Conjugates (ADCs).

The new data strengthens VivoSim's positioning in the growing

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

Wed, 16 Sep 2026 08:05:00 -0400

New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities

The new data strengthens VivoSim's positioning in the growing

VivoSim Labs plans rat liver model to pair with human platform

Tue, 01 Sep 2026 08:06:07 -0400

VivoSim Labs, Inc. (Nasdaq: VIVS) announced plans to develop a rat liver model that would complement its existing NAMkind human liver platform, according to a press release from the San Diego-based company.

The planned model is intended to help pharmaceutical companies determine when liver toxicity observed in rats may be species-specific and not relevant to humans. VivoSim's current human liver model is designed to identify human toxicity that may not appear in animal studies, while the rat model would provide the reverse capability.

"This gives us the ability to look at the same toxicity question from both sides," said Keith Murphy, Executive

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

Tue, 01 Sep 2026 08:05:00 -0400

New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced plans to develop a rat liver model that will complement its existing NAMkind™ human liver platform and expand the Company’s liver toxicology capabilities.

The new model is designed to address a longstanding challenge in drug development: toxicity observed in rats does not always

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

Tue, 01 Sep 2026 08:05:00 -0400

New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans

The new model is designed to address a longstanding challenge in drug development: toxicity observed in rats does not always

Form 8-K VivoSim Labs, INC. For: Aug 17

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961380.html

Form 8-K VivoSim Labs, INC. For: Aug 17

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961380.html

Form ARS VivoSim Labs, INC. For: Mar 31

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961400.html

Form ARS VivoSim Labs, INC. For: Mar 31

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961400.html

Form DEF 14A VivoSim Labs, INC. For: Sep 30

Fri, 21 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260821/26961302.html

Form DEF 14A VivoSim Labs, INC. For: Sep 30

Fri, 21 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260821/26961302.html

Form SCHEDULE 13G/A VivoSim Labs, INC. Filed by: Esousa Group Holdings LLC

Mon, 17 Aug 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260817/26939365.html

Form SCHEDULE 13G/A VivoSim Labs, INC. Filed by: Esousa Group Holdings LLC

Mon, 17 Aug 2026 21:00:00 -0400

si-local-file:///var/storage/secattach/20260817/26939365.html

Form PRER14A VivoSim Labs, INC.

Thu, 13 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260813/26922529.html

Form PRER14A VivoSim Labs, INC.

Thu, 13 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260813/26922529.html

Form 10-Q VivoSim Labs, INC. For: Jun 30

Wed, 12 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260812/26912823.html

Form 10-Q VivoSim Labs, INC. For: Jun 30

Wed, 12 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260812/26912823.html

Form EFFECT VivoSim Labs, INC.

Tue, 11 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260811/26900698.html

Form EFFECT VivoSim Labs, INC.

Tue, 11 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260811/26900698.html

Form PRE 14A VivoSim Labs, INC. For: Sep 30

Mon, 10 Aug 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260810/26895333.html

Form PRE 14A VivoSim Labs, INC. For: Sep 30

Mon, 10 Aug 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260810/26895333.html

VivoSim Labs regains Nasdaq compliance after cash infusion

Thu, 06 Aug 2026 08:05:44 -0400

VivoSim Labs, Inc. (Nasdaq: VIVS) announced it received notice from Nasdaq on August 4, 2026, that the company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2.5 million.

The compliance was achieved following several financial events that occurred after the close of its fiscal year ended March 31, 2026. The company received a $5.0 million milestone payment from Eli Lilly and Company, along with $1.0 million in cash released from escrow on July 22, 2026, both tied to the company's prior sale of its FXR program to Eli Lilly.

On July 17, 2026, VivoSim completed

Form 8-K VivoSim Labs, INC. For: Aug 06

Thu, 06 Aug 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260806/26879366.html